Insight into del17p low‐frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial

Insight into del17p low‐frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial

Summary The clinical significance of low‐frequency deletions of 17p13 [tumour protein p53 (TP53)] in patients with chronic lymphocytic leukaemia (CLL) is currently unclear. Low‐frequency del17p clones (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2021-05, Vol.193 (3), p.556-560
Hauptverfasser: Do, Cuc, Best, O. Giles, Thurgood, Lauren, Hotinski, Anya, Apostolou, Sinoula, Mulligan, Stephen P., Lower, Karen, Kuss, Bryone
Format: Artikel
Sprache:eng
Schlagworte:
Chronic lymphocytic leukemia
CLL
CLL FISH
CLL TP53
Cloning
Consortia
Hematology
Leukemia
Lymphoma
p53 Protein
Survival
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary The clinical significance of low‐frequency deletions of 17p13 [tumour protein p53 (TP53)] in patients with chronic lymphocytic leukaemia (CLL) is currently unclear. Low‐frequency del17p clones (
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17394